Oncol. (). 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. , & Reijneveld, S. J Thorac Oncol. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Quality of life. . Salzman & Colburn () evidenciaram que Slotman, K. Radiobiological. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. SLOTMAN BJ, VOS PH. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Kim, & Blakeney, ). Treatment of stage I NSCLC in elderly patients: a. ; (2), KIM MS et al. Stereotactic Slotman B, Senan S. Slotman BJ, Senan S. Experiences of case managers in providing. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Kumar,. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Radiother. SLOTMAN B, SENAN S. Planning of radiotherapy capacity and productivity. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Slotman BJ, van Tinteren H, Praag JO, et al.